Table 8.

Clinical features of own cases

Pat.	Age/sex	Cutaneous lesions	Extracutaneous manifestations	Genetics *	Initial treatment	Response	Site of relapse	Salvage therapy	Outcome (months)
a	60/m	Thorax	BM, LN, nasopharynx	mos46,XY/45,XY, t(12;15) (p11;q11)	Vincristine, daunorubicin, prednisolone, HAM	CR	BM	ICE	40 DOD
b	71/m	Trunk	BM, leukemia, LN	46, XY	DA, ETI	CR	Skin, BM	Cytarabine, CHOP, FC	18 DOD
c	74/w	Scalp, trunk, upper arms	BM, leukemia	mos46,XX/44,XX,-9	CHOP	CR	BM, leukemia, spleen	Palliative	8 DOD
d	23/m	Diffuse	BM	46, XY	CHOP, MTX (i.th.) autologous PBSCT	CR	Skin, BM, LN, CNS, spleen	ESHAR allo-TX	20 in CR d+52 therapy related
e	32/m	Face, lower legs	BM, leukemia LN, CNS	rev ish dim 5q21-q32rev ish dim 9 rev ish dim	CHOP, MTX (i.th.) autologous PBSCT	CR	Skin, BM, leukemia, LN, CNS,	T-ALL regimen	13 DOD
				13q rev ish enh 14q32
f	67/f	Mamma	No	ND	DA	CR			4+under therapy

^*In all cases except case e, classical cytogenetics was performed. Case e was investigated by comparative genomic hybidization.

ALL: acute lymphoblastic leukemia; ATG: antithymocyte globulin; BM: bone marrow; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CNS: central nervous system; DA: daunorubicin, cytarabine; DOD: died of disease; ESHAP: etoposide, methylprednisone, cytarabine, cisplatin; ETI: idarubicine, thioguanine, etoposide; FC: fludarabine, cyclophosphamide; HAM: high-dose cytarabine, mitoxantrone; ICE: idarubicin, cytarabine, etoposide; i.th: intrathecal; LN: lymph nodes; MTX: methotrexate; CR: complete remission.